Last updated on July 2019

A Study to Assess the Efficacy Safety and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis

Brief description of study

Study of the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of KPL-716 in subjects with prurigo nodularis.

Detailed Study Description

This is a Phase 2a/b randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK and immunogenicity of KPL-716 administered subcutaneously (SC) in subjects with prurigo nodularis experiencing pruritus. The Phase 2a portion of the study will enroll up to 100 subjects and will include 2 arms: one active arm and one placebo arm.

Following analysis of the Phase 2a portion of the study (milestone dates above), enrollment into the Phase 2b portion may be initiated.

Clinical Study Identifier: NCT03816891

Find a site near you

Start Over

Study Site 104

Anniston, AL United States
  Connect »

Site 125

Phoenix, AZ United States
  Connect »

Site 127

Scottsdale, AZ United States
  Connect »

Site 116

Fountain Valley, CA United States
  Connect »

Study Site 102

Los Angeles, CA United States
  Connect »

Study Site 107

Largo, FL United States
  Connect »

Site 111

Pembroke Pines, FL United States
  Connect »

Site 117

Tampa, FL United States
  Connect »

Site 105

Boise, ID United States
  Connect »

Site 110

Beverly, MA United States
  Connect »

Site 113

Fort Gratiot, MI United States
  Connect »

Site 118

Troy, MI United States
  Connect »

Site 108

Omaha, NE United States
  Connect »

Site 121

Fairborn, OH United States
  Connect »

Study Site 101

Houston, TX United States
  Connect »

Site 106

Pflugerville, TX United States
  Connect »

Site 128

San Antonio, TX United States
  Connect »

Site 115

Spokane, WA United States
  Connect »

Site 301

Red Deer, AB Canada
  Connect »

Site 306

Fredericton, NB Canada
  Connect »

Site 305

London, ON Canada
  Connect »

Site 131

West Palm Beach, FL United States
  Connect »

Site 114

Sandy Springs, GA United States
  Connect »

Site 123

New Albany, IN United States
  Connect »

Site 130

Warren, MI United States
  Connect »

Site 302

Edmonton, AB Canada
  Connect »

Site 307

Barrie, ON Canada
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.